In the uncertain terrain of rare disease medicine, Dianthus Biopharmaceuticals stands at a crossroads — its CAPTIVATE trial has yielded promising data on a C1s inhibitor for CIDP, yet the very pathway it champions is now shadowed by competitor stumbles and the advancing presence of alternative therapies. A Hold rating is not a dismissal of the science, but a philosopher's pause: progress has been made, yet the larger story of who will ultimately serve these patients remains unwritten. In rare disease, timing and sequence are often as consequential as efficacy itself.